Menu
No results found.
Weekly Share Price & Valuation Overview
Cantargia AB (publ)
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- SEK 723.46M
- Enterprise Value Operating value: market cap + total debt − cash.
- SEK 636.93M
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.87
- Shares Outstanding
- 248.61M
- Float Shares
- 242.70M
- Implied Shares Outstanding
- 248.61M
- ROA Return on assets: net income ÷ total assets.
-
-74.42%
- ROE Return on equity: net income ÷ shareholder equity.
-
-1.69%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 2.16
- Total Cash Cash and equivalents.
- SEK 103.93M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- SEK -103.93M
- Revenue per Share (TTM) computed from resolved revenue ÷ shares due to feed inconsistency.
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.